Elucidating these forces is critical for understanding how VDAC oligomerization is regulated under physiological and pathological conditions, such as in cancer, neurodegeneration, and metabolic diseases, where VDAC function is often disrupted. This evidence concerns the gene VDAC1 and metabolic disease.